New drug combo aims to reignite immune attack on tough childhood cancer

NCT ID NCT07085338

Recruiting now Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests whether adding an experimental immune-boosting drug (N-803) to standard chemoimmunotherapy can help children and young adults whose neuroblastoma has returned or not responded to treatment. About 54 participants will receive the combination to see if it is safe and works better than the current approach. The goal is to shrink tumors and improve survival without causing severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA RECURRENT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Children's Hospital of Colorado
NOT_YET_RECRUITING

Aurora, Colorado, 80902, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Motts Childrens Hospital
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States
St. Jude Children's Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States

Contact Email: •••••@•••••
University of California San Francisco
NOT_YET_RECRUITING

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.